Continuous Glucose Monitoring (CGM) helps people with diabetes see not only where their glucose is right now, but where it’s going. With 288 readings per day, the Eversense XL CGM System shows trend arrows revealing the speed and direction of your glucose levels. This information helps you proactively manage your highs and lows, instead of trying to overcorrect after experiencing a high or low. People using Eversense say it helps them feel more confident about controlling their diabetes,1 and we hope it does the same for you.
A New Alternative to Traditional CGM
A New Alternative to Traditional CGM
Eversense improves on traditional CGM to empower you to proactively manage your diabetes.
Alerts you can see, feel and hear
Eversense XL can send you alerts to warn you of highs and lows, before you get there. Alerts can include pop-up messages on your phone, alerts or vibrations on your arm to alert you to highs and lows, based on your customized settings.
Learn More
No Sensor Self-Insertions
Eversense XL is inserted by your healthcare provider 2-3 times per year, letting you avoid the burdensome self-insertion process every 7-14 days. Your healthcare provider can do the insertion right in the clinic and quickly get you back to your life.
Learn More
No Receiver Required
With Eversense XL, you can see your readings directly on your compatible mobile device without needing a separate receiver. And with readings every 5 minutes, you can see where you are now and where you’re headed with the trend arrows.2
Learn MoreNot just better health, a better quality of life
Having diabetes is hard enough. Eversense wants to help make it easier to manage. As part of our European clinical trial, we asked users how Eversense impacted their life.*
Learn More
1 Precise II study, psychosocial assessment. 2 Data on file.
* Kropff, J., Choudhary, P., Neupane, S., Barnard, K., Bain, S. C., Kapitza, C., ... & DeVries, J. H. (2017). Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care, 40(1), 63-68. 1. Kropff, J., Choudhary, P., Neupane, S., Barnard, K., Bain, S. C., Kapitza, C., ... & DeVries, J. H. (2017). Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care, 40(1), 63-68.
MKT-001283 Rev2
